Stem Cell-Generated Stomach Organoids to Boost Gastric Disease Research
|
By LabMedica International staff writers Posted on 24 Jan 2017 |

Image: A confocal microscopic image showing tissue-engineered human stomach tissues from the corpus/fundus region, which produces acid and digestive enzymes (Photo courtesy of Cincinnati Children\'s Hospital Medical Center).
Research on gastric diseases will benefit from the development of complex organoid structures containing functional stomach fundic epithelium tissue that were generated from human pluripotent stem cells.
Despite the global prevalence of gastric disease, there are few adequate models in which to study the fundus epithelium of the human stomach. To fill this gap, investigators at Cincinnati Children's Hospital Medical Center differentiated human pluripotent stem cells (hPSCs) into gastric organoids containing fundic epithelium by first identifying and then recapitulating key events in embryonic fundus development.
The investigators reported in the January 4, 2017, online edition of the journal Nature that disruption of Wnt/beta-catenin signaling in mouse embryos led to conversion of fundic to antral epithelium, and that beta-catenin activation in hPSC-derived foregut progenitors promoted the development of human fundic-type gastric organoids (hFGOs). The investigators then used hFGOs to identify temporally distinct roles for multiple signaling pathways in epithelial morphogenesis and differentiation of fundic cell types, including chief cells and functional parietal cells.
"Now that we can grow both antral- and corpus/fundic-type human gastric mini-organs, it is possible to study how these human gastric tissues interact physiologically, respond differently to infection, injury and react to pharmacologic treatments," said senior author Dr. James M. Wells, director of the pluripotent stem cell facility at Cincinnati Children's Hospital Medical Center. "Diseases of the stomach impact millions of people in the United States and gastric cancer is the third leading cause of cancer-related deaths worldwide."
Despite the global prevalence of gastric disease, there are few adequate models in which to study the fundus epithelium of the human stomach. To fill this gap, investigators at Cincinnati Children's Hospital Medical Center differentiated human pluripotent stem cells (hPSCs) into gastric organoids containing fundic epithelium by first identifying and then recapitulating key events in embryonic fundus development.
The investigators reported in the January 4, 2017, online edition of the journal Nature that disruption of Wnt/beta-catenin signaling in mouse embryos led to conversion of fundic to antral epithelium, and that beta-catenin activation in hPSC-derived foregut progenitors promoted the development of human fundic-type gastric organoids (hFGOs). The investigators then used hFGOs to identify temporally distinct roles for multiple signaling pathways in epithelial morphogenesis and differentiation of fundic cell types, including chief cells and functional parietal cells.
"Now that we can grow both antral- and corpus/fundic-type human gastric mini-organs, it is possible to study how these human gastric tissues interact physiologically, respond differently to infection, injury and react to pharmacologic treatments," said senior author Dr. James M. Wells, director of the pluripotent stem cell facility at Cincinnati Children's Hospital Medical Center. "Diseases of the stomach impact millions of people in the United States and gastric cancer is the third leading cause of cancer-related deaths worldwide."
Latest BioResearch News
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







